Scott D. Solomon, MD
Credit: Brigham and Women’s Hospital
A secondary analysis of FINEARTS-HF found finerenone could prevent outpatient worsening heart failure (HF) events requiring oral diuretic intensification in people with mildly reduced or preserved ejection fraction.
Approximately 6000 participants with HF reported frequent outpatient oral diuretic intensification, which was linked to an elevated risk of subsequent mortality. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist (nsMRA), reduced oral diuretic intensification rates by 11%.
“These results support the use of outpatient oral diuretic intensification as an early marker of worsening HF and indicate that the benefit of finerenone in decreasing worsening HF events in patients with HF with mildly reduced or preserved ejection fraction extends to…